Subject terms
cancer
ADVERSE EVENTS, CANCER, ACUTE LEUKAEMIA
Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby restoring normal tissue functionRevumenib, a potent and selective oral inhibitor of the menin–KMT2A interaction, is associated with a low frequency of treatment-related adverse events and promising clinical activity in patients with relapsed or refractory acute leukaemia.